Zanubrutinib is an oral small molecule targeted drug, belonging to the Bruton tyrosine kinase (BTK) inhibitor, mainly used for the treatment of hematological malignancies such as B-cell lymphoma. Its mechanism of action is to inhibit the activity of BTK enzyme, block the B cell receptor signaling pathway, and thus inhibit the proliferation and survival of malignant B cells.

1、 Pharmacological effects and indications

1. Mechanism of action:

BTK is a key regulatory factor for B cell development and survival. Zebutinib irreversibly binds to BTK, inhibiting its phosphorylation and downstream signaling, reducing cancer cell growth and spread.

2. Indications (subject to medical advice):

Mantle cell lymphoma (MCL)

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Fahrenheit macroglobulinemia (WM)

Borderline lymphoma (MZL)

2、 Usage and dosage

1. Conventional usage:

Usually taken orally, twice a day, 160mg each time (the specific dosage needs to be adjusted according to the condition).

2. Adjustment principle:

Patients with severe liver and kidney dysfunction need to reduce their dosage.

When specific adverse reactions occur (such as bleeding, infection), medication should be paused or adjusted.

3、 Adverse reactions

1. Common reactions:

Hematological system: neutropenia, thrombocytopenia.

Digestive system: diarrhea, nausea.

Other: fatigue, muscle pain.

2. Serious risks:

Bleeding (such as intracranial hemorrhage, gastrointestinal bleeding).

Opportunistic infections (such as pneumonia, fungal infections).

Heart problems (such as atrial fibrillation).

4、 Precautions and taboos

1. Monitoring requirements:

Regularly check blood routine, liver and kidney function, and electrocardiogram.

Pay attention to signs of infection (fever, cough) or abnormal bleeding (nosebleeds, bruising).

2. Taboo population:

People who are allergic to the ingredients of Zebutinib.

Pregnant or lactating women (may affect the fetus or infant).

3. Drug interactions:

Avoid combination with potent CYP3A inhibitors (such as ketoconazole) or inducers (such as rifampicin).

5、 Medical guidance

Zebutinib is a prescription drug that must be strictly taken according to the doctor's guidance. Do not adjust the dosage or discontinue the medication on your own. If any of the following situations occur during treatment, seek medical attention immediately:

Persistent fever or infection symptoms.

Severe headache, chest pain, or difficulty breathing.

Unexplained bruising or bleeding.

By selectively inhibiting the BTK pathway, Zebutinib provides more precise treatment options for some lymphoma patients, but the risk and benefit need to be evaluated based on individual circumstances.